```

[Federal Register Volume 89, Number 224 (Wednesday, November 20, 2024)]
[Notices]
[Pages 91773-91774]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-27096]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License, Inter-Institutional 
Agreement-Institution Lead: Peptides and Peptide Microarrays for 
Detection and Differentiation of Antibody Responses to Ebola Virus and 
Other Pathogens.

AGENCY: National Institutes of Health, National Institute of Allergy 
and Infectious Diseases.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institute of Allergy and Infectious Diseases, an 
institute of the National Institutes of Health, Department of Health 
and

[[Page 91774]]

Human Services, is contemplating the grant of an exclusive, 
sublicensable patent license to The Trustees of Columbia University in 
the City of New York, Columbia Technology Ventures, located in New 
York, New York to practice the inventions embodied in the patent 
applications listed in the SUPPLEMENTARY INFORMATION section of this 
notice.

DATES: Only written comments and/or applications for a license which 
are received by the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases on or 
before December 5, 2024 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated exclusive patent license 
should be directed to: Wade Green, Ph.D., Lead Technology Transfer and 
Patent Specialist, Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852-9804, phone number 
301-761-7505, or [email protected].

SUPPLEMENTARY INFORMATION: The following represents the intellectual 
property to be licensed under the prospective agreement: U.S. 
Provisional Patent Application Serial No. 68/428,826, filed November 
30, 2022, titled ``Peptides And Peptide Microarrays For Detection And 
Differentiation Of Antibody Responses To Ebola Virus And Other 
Pathogens'' (HHS Reference No. E-028-2024-0-US-01) and International 
Patent Application No. PCT/US23/81625, filed on November 29, 2023, 
titled ``Peptides And Peptide Microarrays For Detection And 
Differentiation Of Antibody Responses To Ebola Virus'' (HHS Reference 
No. E-028-2024-0-PC-01). All rights in these inventions have been 
assigned to The Trustees of Columbia University in the City of New 
York, Columbia Technology Ventures and the Government of the United 
States of America.
    The prospective patent license will be for the purpose of 
consolidating the patent rights with The Trustees of Columbia 
University in the City of New York, Columbia Technology Ventures, the 
co-owner of said rights, for commercial development and marketing. 
Consolidation of these co-owned rights is intended to expedite 
development of the invention, consistent with the goals of the Bayh-
Dole Act codified as 35 U.S.C. 200-212.
    The prospective interinstitutional agreement will include an 
exclusive license for NIAID's rights in these jointly owned patents. It 
will be sublicensable, and any sublicenses granted by The Trustees of 
Columbia University in the City of New York Columbia Technology 
Ventures will be subject to the provisions of 37 CFR part 404.
    The subject patent rights are related to novel peptides that enable 
specific and sensitive serological detection of adaptive immune 
responses to a wide range of clinically important high threat pathogens 
circulating in sub-Saharan Africa on a wide range of platforms. These 
assays allow identification of individuals who have been immunized and/
or infected with filoviruses.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and may be granted unless within fifteen (15) days from the date of 
this published notice, the National Insitute of Allergy and Infectious 
Diseases receives written evidence and argument that establishes that 
the grant of the license would not be consistent with the requirements 
of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: November 15, 2024.
Jeremiah D. Mitzelfelt,
Acting Deputy Director, Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-27096 Filed 11-19-24; 8:45 am]
BILLING CODE 4140-01-P
```